Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.
References